Terumo (OTCPK:TRUM.Y) FY Conference Transcript

Terumo Company Conference Call Summary Company Overview - Company: Terumo Corporation - Industry: Medical Technology (MedTech) - CEO: Hikaru Samejima - Sales: $7 billion globally with three main business segments: - Cardiac and Vascular - Terumo Medical Care Solutions (TMCS) - Terumo Blood and Cell Technologies (TBCT) [3][4] Key Points and Arguments Business Segments and Growth - Cardiac and Vascular: - Revenue from vascular access-related products exceeds 70% [7] - Focus on transforming commoditized devices into high-value offerings [7] - Strong growth in vascular intervention market due to technology advancements [7][8] - Terumo Medical Care Solutions (TMCS): - Emphasis on CDMO (Contract Development and Manufacturing Organization) business, which provides drug administration devices [10] - Aiming for $1 billion in sales by the 2030s, with significant growth potential in self-administered drugs [11][12] - Terumo Blood and Cell Technologies (TBCT): - Focus on plasma collection systems, with rapid growth in the U.S. market [12] - Partnership with CSL for plasma collection centers, expecting continued revenue growth [12][13] Financial Performance and Projections - Profitability: - Significant AOP (Adjusted Operating Profit) margin expansion over the last three years, targeting 20% margin for FY 2026 [5][6] - FY 2025 projected revenue growth of 8% and operating profit growth of 24% [5][6] - Acquisitions: - Successful track record in M&A, with a disciplined approach focusing on technological excellence, competitive advantage, synergy, financial profile, and cultural fit [13][14] - Recent acquisition of OrganOx, which is expected to maintain high double-digit growth due to its breakthrough technology in organ transplantation [23][24] Market Position and Strategy - Innovation and R&D: - Commitment to developing category-leading products and solutions for medical challenges [6][9] - Focus on maintaining robust sales growth and margin expansion through innovation and strategic acquisitions [17][18] - Regional Strategy: - U.S. market remains strategically important, with plans to reinforce therapeutic business [33] - Targeting growth in emerging markets like China and India due to increasing medical access [34] Challenges and Risks - Market Competition: - Acknowledgment of competitive pressures in the U.S. medtech market [33] - Ongoing evaluation of business performance to identify non-performing segments for potential divestment [20] - Regulatory Environment: - Awareness of potential impacts from changes in healthcare policies, such as ACA-enhanced subsidy loss [35] Additional Important Insights - OrganOx Technology: - NMP (Normothermic Machine Perfusion) technology is expected to unlock bottlenecks in organ supply, significantly reducing the discard rate of livers [27] - Plans to expand into kidney transplantation by 2030 [30] - CDMO Market Potential: - The CDMO market is highly attractive, with a focus on innovative device development and manufacturing capabilities [11][39] - Long-term Vision: - Terumo aims to become a global top-tier medtech leader, driven by innovation and a commitment to patient care [17][18]